Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2012, Article ID 525936, 8 pages
http://dx.doi.org/10.1155/2012/525936
Review Article

The Role of Thyrotrophin Receptor Antibody Assays in Graves’ Disease

1Department of Medicine, Caerphilly Miners’ Hospital, St. Martin’s Road, Caerphilly CF83 2WW, UK
2Centre for Endocrine and Diabetes Sciences, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK

Received 31 October 2011; Accepted 27 January 2012

Academic Editor: Juan Carlos Galofré

Copyright © 2012 C. Kamath et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Bartalena, “The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 592–599, 2011. View at Publisher · View at Google Scholar
  2. T. J. Smith, “Pathogenesis of Graves' orbitopathy: a 2010 update,” Journal of Endocrinological Investigation, vol. 33, no. 6, pp. 414–421, 2010. View at Google Scholar · View at Scopus
  3. Y. Tomer, “Genetic susceptibility to autoimmune thyroid disease: past, present, and future,” Thyroid, vol. 20, no. 7, pp. 715–725, 2010. View at Google Scholar · View at Scopus
  4. Y. Tomer and A. Huber, “The etiology of autoimmune thyroid disease: a story of genes and environment,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 231–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. O. J. Brand and S. C. L. Gough, “Genetics of thyroid autoimmunity and the role of the TSHR,” Molecular and Cellular Endocrinology, vol. 322, no. 1-2, pp. 135–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. L. Tanda, E. Piantanida, A. Lai et al., “Thyroid autoimmunity and environment,” Hormone and Metabolic Research, vol. 41, no. 6, pp. 436–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. K. Eckstein, K. T. Johnson, M. Thanos, J. Esser, and M. Ludgate, “Current insights into the pathogenesis of Graves' orbitopathy,” Hormone and Metabolic Research, vol. 41, no. 6, pp. 456–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. D. Adams and H. D. Purves, “Abnormal responses in the assay of thyrotopin,” Proceedings of the University of Otago Medical School, vol. 34, pp. 11–20, 1956. View at Google Scholar
  9. J. P. Kriss, V. Pleshakov, and J. R. Chien, “Isolation and identification of the long acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxoedema,” The Journal of clinical endocrinology and metabolism, vol. 24, pp. 1005–1028, 1964. View at Google Scholar
  10. B. R. Smith and R. Hall, “The thyroid stimulating hormone receptor and thyroid stimulating antibodies,” Journal of Endocrinology, vol. 63, no. 2, pp. 59–60, 1974. View at Google Scholar · View at Scopus
  11. J. Sanders, D. Y. Chirgadze, P. Sanders et al., “Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody,” Thyroid, vol. 17, no. 5, pp. 395–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Rees Smith, J. Sanders, M. Evans, T. Tagami, and J. Furmaniak, “TSH receptor—autoantibody interactions,” Hormone and Metabolic Research, vol. 41, no. 6, pp. 448–455, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Sanders, R. N. Miguel, J. Bolton et al., “Molecular interactions between the TSH receptor and a thyroid-stimulating monoclonal autoantibody,” Thyroid, vol. 17, no. 8, pp. 699–706, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Ando, R. Latif, and T. F. Davies, “Antibody-induced modulation of TSH receptor post-translational processing,” Journal of Endocrinology, vol. 195, no. 1, pp. 179–186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Zöphel, D. Roggenbuck, and M. Schott, “Clinical review about TRAb assay's history,” Autoimmunity Reviews, vol. 9, no. 10, pp. 695–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Michalek, S. A. Morshed, R. Latif, and T. F. Davies, “TSH receptor autoantibodies,” Autoimmunity Reviews, vol. 9, no. 2, pp. 113–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. A. Morshed, T. Ando, R. Latif, and T. F. Davies, “Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades,” Endocrinology, vol. 151, no. 11, pp. 5537–5549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. D. C. Allen, T. Okada, H. L. Tang, and J. G. Cyster, “Imaging of germinal center selection events during affinity maturation,” Science, vol. 315, no. 5811, pp. 528–531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. D. C. Allen, T. Okada, and J. G. Cyster, “Germinal-central cell organization and cellular dynamics,” Immunity, vol. 27, no. 2, pp. 190–202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Mueller, H. Jaeschke, R. Günther, and R. Paschke, “The hinge region: an important receptor component for GPHR function,” Trends in Endocrinology and Metabolism, vol. 21, no. 2, pp. 111–122, 2010. View at Publisher · View at Google Scholar
  21. S. Mueller, M. W. Szkudlinski, J. Schaarschmidt, R. Günther, R. Paschke, and H. Jaeschke, “Identification of novel TSH interaction sites by systematic binding analysis of the TSHR hinge region,” Endocrinology, vol. 152, no. 8, pp. 3268–3278, 2011. View at Publisher · View at Google Scholar
  22. G. Vassart, L. Pardo, and S. Costagliola, “A molecular dissection of the glycoprotein hormone receptors,” Trends in Biochemical Sciences, vol. 29, no. 3, pp. 119–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Sanders, J. Bolton, P. Sanders et al., “Effects of TSH receptor mutations on binding and biological activity of monoclonal antibodies and TSH,” Thyroid, vol. 16, no. 12, pp. 1195–1206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. Chen, P. Pichurin, Y. Nagayama, F. Latrofa, B. Rapoport, and S. M. McLachlan, “The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1897–1904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. F. Davies, T. Ando, R. Y. Lin, Y. Tomer, and R. Latif, “Thyrotropin receptor-associated diseases: from adenomata to Graves disease,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 1972–1983, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Atger, M. Misrahi, J. Young et al., “Autoantibodies interacting with purified native thyrotropin receptor,” European Journal of Biochemistry, vol. 265, no. 3, pp. 1022–1031, 1999. View at Publisher · View at Google Scholar
  27. J. Sanders, M. Evans, L. D. K. E. Premawardhana et al., “Human monoclonal thyroid stimulating autoantibody,” Lancet, vol. 362, no. 9378, pp. 126–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Lytton and G. J. Kahaly, “Bioassays for TSH-receptor autoantibodies: an update,” Autoimmunity Reviews, vol. 10, no. 2, pp. 116–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. A. Ajjan and A. P. Weetman, “Techniques to quantify TSH receptor antibodies,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 8, pp. 461–468, 2008. View at Publisher · View at Google Scholar
  30. U. Feldt-Rasmussen, “Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor,” Clinical Chemistry, vol. 42, no. 1, pp. 160–163, 1996. View at Google Scholar · View at Scopus
  31. B. R. Smith and R. Hall, “The thyroid stimulating hormone receptor and thyroid stimulating antibodies,” Journal of Endocrinology, vol. 63, no. 2, pp. 59–60, 1974. View at Google Scholar · View at Scopus
  32. S. Costagliola, N. G. Morgenthaler, R. Hoermann et al., “Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 1, pp. 90–97, 1999. View at Publisher · View at Google Scholar
  33. D. Villalta, E. Orunesu, R. Tozzoli et al., “Analytical and diagnostic accuracy of “second generation” assays for thyrotrophin receptor antibodies with radioactive and chemiluminescent tracers,” Journal of Clinical Pathology, vol. 57, no. 4, pp. 378–382, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Paunkovic and N. Paunkovic, “Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis,” Hormone and Metabolic Research, vol. 38, no. 1, pp. 53–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. R. Smith, J. Bolton, S. Young et al., “A new assay for thyrotropin receptor autoantibodies,” Thyroid, vol. 14, no. 10, pp. 830–835, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Kamijo, K. Ishikawa, and M. Tanaka, “Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith,” Endocrine Journal, vol. 52, no. 5, pp. 525–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Mukuta, H. Tamai, A. Oshima et al., “Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin,” Clinical Endocrinology, vol. 40, no. 2, pp. 215–219, 1994. View at Google Scholar · View at Scopus
  38. A. Theodoraki, G. Jones, J. Parker et al., “Performance of a third-generation TSH-receptor antibody in a UK clinic,” Clinical Endocrinology, vol. 75, no. 1, pp. 127–133, 2011. View at Publisher · View at Google Scholar
  39. M. Schott, D. Hermsen, M. Broecker-Preuss et al., “Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial,” Clinical Endocrinology, vol. 71, no. 4, pp. 566–573, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. N. G. Morgenthaler, I. Pompel, G. Aust, J. Seissler, and W. A. Scherbaum, “Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor,” Hormone and Metabolic Research, vol. 30, no. 3, pp. 162–168, 1998. View at Google Scholar · View at Scopus
  41. K. Kamijo, A. Nagata, and Y. Sato, “Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells,” Endocrine Journal, vol. 46, no. 3, pp. 397–403, 1999. View at Google Scholar · View at Scopus
  42. M. K. Gupta, “Thyrotropin-receptor antibodies in thyroid diseases: advances in detection techniques and clinical applications,” Clinica Chimica Acta, vol. 293, no. 1-2, pp. 1–29, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. G. C. J. Hovens, A. M. J. Buiting, M. Karperien et al., “A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease,” Clinical Endocrinology, vol. 64, no. 4, pp. 429–435, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Evans, N. G. Morgenthaler, S. Lee et al., “Development of a luminescent bioassay for thyroid stimulating antibodies,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 1, pp. 374–377, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. S. D. Lytton, K. A. Ponto, M. Kanitz, N. Matheis, L. D. Kohn, and G. J. Kahaly, “A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of graves' orbitopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2123–2131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Kamijo, H. Murayama, T. Uzu, K. Togashi, and G. J. Kahaly, “A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (Mc4) is more useful in differentiation of graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells,” Thyroid, vol. 20, no. 8, pp. 851–856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Zimmermann-Belsing, B. Nygaard, Å. K. Rasmussen, and U. Feldt-Rasmussen, “Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease,” European Journal of Endocrinology, vol. 146, no. 2, pp. 173–177, 2002. View at Google Scholar
  48. B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, and O. E. Janssen, “Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease,” Thyroid, vol. 15, no. 9, pp. 1047–1054, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Schott, A. Eckstein, H. S. Willenberg, T. B. T. Nguyen, N. G. Morgenthaler, and W. A. Scherbaum, “Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies,” Hormone and Metabolic Research, vol. 39, no. 1, pp. 56–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Cappelli, E. Gandossi, M. Castellano et al., “Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study,” Endocrine Journal, vol. 54, no. 5, pp. 713–720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Massart, J. Gibassier, and M. d'Herbomez, “Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay,” Clinica Chimica Acta, vol. 407, no. 1-2, pp. 62–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. I. B. Pedersen, A. Handberg, N. Knudsen, L. Heickendorff, and P. Laurberg, “Assays for thyroid-stimulating hormone receptor antibodies employing different ligands and ligand partners may have similar sensitivity and specificity but are not interchangeable,” Thyroid, vol. 20, no. 2, pp. 127–133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,” Thyroid, vol. 21, no. 6, pp. 593–646, 2011. View at Publisher · View at Google Scholar
  54. O. E. Okosieme, D. Chan, S. A. Price, J. H. Lazarus, and L. D. K. E. Premawardhana, “The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism,” Clinical Endocrinology, vol. 72, no. 1, pp. 122–127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. Franklyn, “What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism?” Clinical Endocrinology, vol. 72, no. 1, pp. 11–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Cappelli, I. Pirola, E. De Martino et al., “The role of imaging in Graves' disease: a cost-effectiveness analysis,” European Journal of Radiology, vol. 65, no. 1, pp. 99–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Vaidya, G. R. Williams, P. Abraham, and S. H. S. Pearce, “Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists,” Clinical Endocrinology, vol. 68, no. 5, pp. 814–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. G. J. Kahaly, L. Bartalena, and L. Hegedüs, “The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective,” Thyroid, vol. 21, no. 6, pp. 585–591, 2011. View at Publisher · View at Google Scholar
  59. J. H. Mestman, “Hyperthyroidism in pregnancy,” Clinical Obstetrics and Gynecology, vol. 40, no. 1, pp. 45–64, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. G. N. Burrow, “Thyroid function and hyperfunction during gestation,” Endocrine Reviews, vol. 14, no. 2, pp. 194–202, 1993. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Zimmerman, “Fetal and neonatal hyperthyroidism,” Thyroid, vol. 9, no. 7, pp. 727–733, 1999. View at Google Scholar · View at Scopus
  62. A. P. Weetman, “Immunity, thyroid function and pregnancy: molecular mechanisms,” Nature Reviews Endocrinology, vol. 6, no. 6, pp. 311–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Luton, I. Le Gac, E. Vuillard et al., “Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 11, pp. 6093–6098, 2005. View at Publisher · View at Google Scholar
  64. S. Clavel, A. M. Madec, H. Bornet, P. Deviller, A. Stefanutti, and J. Orgiazzi, “Anti TSH-receptor antibodies in pregnant patients with autoimmune thyroid disorder,” British Journal of Obstetrics and Gynaecology, vol. 97, no. 11, pp. 1003–1008, 1990. View at Google Scholar · View at Scopus
  65. N. Hamada, N. Momotani, N. Ishikawa et al., “Persistent high TRAb values during pregnancy predict increased risk of neonatal hyperthyroidism following radioiodine therapy for refractory hyperthyroidism,” Endocrine Journal, vol. 58, no. 1, pp. 55–58, 2011. View at Publisher · View at Google Scholar
  66. A. Stagnaro-Green, M. Abalovich, E. Alexander et al., “Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum,” Thyroid, vol. 21, no. 10, pp. 1081–1125, 2011. View at Publisher · View at Google Scholar
  67. A. Weetman, “Immune reconstitution syndrome and the thyroid,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 23, no. 6, pp. 693–702, 2009. View at Publisher · View at Google Scholar
  68. K. A. Ponto, M. Kanitz, P. D. Olivo, S. Pitz, N. Pfeiffer, and G. J. Kahaly, “Clinical relevance of thyroid-stimulating immunoglobulins in Graves' ophthalmopathy,” Ophthalmology, vol. 118, no. 11, pp. 2279–2285, 2011. View at Publisher · View at Google Scholar
  69. A. P. Weetman, “The immunomodulatory effects of antithyroid drugs,” Thyroid, vol. 4, no. 2, pp. 145–146, 1994. View at Google Scholar · View at Scopus
  70. C. Carella, G. Mazziotti, F. Sorvillo et al., “Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: Evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period,” Thyroid, vol. 16, no. 3, pp. 295–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. E. D. Mukhtar, B. R. Smith, and G. A. Pyle, “Relation of thyroid stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs,” Lancet, vol. I, no. 7909, pp. 713–715, 1975. View at Google Scholar · View at Scopus
  72. P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, and O. Törring, “TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study,” European Journal of Endocrinology, vol. 158, no. 1, pp. 69–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. A. M. McGregor, S. M. McLachlan, B. R. Smith, and R. Hall, “Effect of irradiation on thyroid-autoantibody production,” Lancet, vol. 2, no. 8140, pp. 442–444, 1979. View at Google Scholar · View at Scopus
  74. M. Schott, N. G. Morgenthaler, R. Fritzen et al., “Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease,” Hormone and Metabolic Research, vol. 36, no. 2, pp. 92–96, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. N. R. Syme, A. D. Toft, M. Stoddart, and G. J. Beckett, “Clinical performance of the Roche cobas e411 automated assay system for thyrotropin-receptor antibodies for the diagnosis of Graves' disease,” Annals of Clinical Biochemistry, vol. 48, no. 5, pp. 471–473, 2011. View at Publisher · View at Google Scholar